Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Altimmune (ALT) Depreciation & Amortization - Total (2016 - 2017)

Altimmune (ALT) has disclosed Depreciation & Amortization - Total for 6 consecutive years, with $33007.0 as the latest value for Q1 2017.

  • On a quarterly basis, Depreciation & Amortization - Total fell 12.45% to $33007.0 in Q1 2017 year-over-year; TTM through Dec 2017 was $33007.0, a 76.99% decrease, with the full-year FY2016 number at $143437.0, up 1.29% from a year prior.
  • Depreciation & Amortization - Total was $33007.0 for Q1 2017 at Altimmune, roughly flat from $33066.0 in the prior quarter.
  • In the past five years, Depreciation & Amortization - Total ranged from a high of $52602.0 in Q1 2013 to a low of $32235.0 in Q3 2016.
  • A 5-year average of $38264.3 and a median of $37106.0 in 2015 define the central range for Depreciation & Amortization - Total.
  • Peak YoY movement for Depreciation & Amortization - Total: crashed 37.14% in 2013, then grew 10.22% in 2016.
  • Altimmune's Depreciation & Amortization - Total stood at $43438.0 in 2013, then decreased by 15.54% to $36686.0 in 2014, then fell by 10.58% to $32806.0 in 2015, then increased by 0.79% to $33066.0 in 2016, then dropped by 0.18% to $33007.0 in 2017.
  • Per Business Quant, the three most recent readings for ALT's Depreciation & Amortization - Total are $33007.0 (Q1 2017), $33066.0 (Q4 2016), and $32235.0 (Q3 2016).